ArticleMedical oncology (Northwood, London, England)2017

First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.

Roberto Castelli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.